Gain Therapeutics, Inc. (GANX): Price and Financial Metrics
GANX Price/Volume Stats
| Current price | $3.18 | 52-week high | $6.19 |
| Prev. close | $3.15 | 52-week low | $2.00 |
| Day low | $3.00 | Volume | 71,300 |
| Day high | $3.26 | Avg. volume | 156,778 |
| 50-day MA | $4.15 | Dividend yield | N/A |
| 200-day MA | $3.54 | Market Cap | 51.58M |
GANX Stock Price Chart Interactive Chart >
Gain Therapeutics, Inc. (GANX) Company Bio
Gain Therapeutics, Inc., a development stage biotechnology company, develops novel therapeutics to treat rare genetic and neurological disorders caused by protein misfolding in Switzerland and Spain. The company through its in-licensed proprietary Site-Directed Enzyme Enhancement Therapy platform, discovers novel allosteric sites on misfolded proteins, identifies proprietary binding sites, and restores protein folding. It has a research collaboration agreement with Sumitomo Dainippon Pharma Co., Ltd. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Latest GANX News From Around the Web
Below are the latest news stories about GAIN THERAPEUTICS INC that investors may wish to consider to help them evaluate GANX as an investment opportunity.
Bears are Losing Control Over Gain Therapeutics, Inc. (GANX), Here's Why It's a 'Buy' NowAfter losing some value lately, a hammer chart pattern has been formed for Gain Therapeutics, Inc. (GANX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. |
Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap ResearchBETHESDA, Md., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s Chief Executive Officer, Matthias Alder, will participate in a fireside chat, hosted by FORCE Family Office, with John Vandermosten, CFA, Senior Analyst for Zacks Small-Cap Research taking place Tuesday, December 5, 2023. Fireside Chat |
Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis ModelCompounds significantly restored β-Gal function and reduced intracellular toxic substrates in model of GM1 gangliosidosis Results published in PLOS ONE in collaboration with Institute for Research in Biomedicine BETHESDA, Md., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the publication of preclinical data identi |
Gain Therapeutics to Participate in AI Driven Drug Discovery SummitBETHESDA, Md., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executive Officer, will participate on a panel during the AI Driven Drug Discovery Summit taking place at the Sheraton Boston Hotel, in Boston, Massachusetts December 5-6, 2023. AI Driven Drug Discovery SummitDate: Wednesday, D |
Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment OptionBETHESDA, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the closing of an underwritten public offering of 2,545,000 shares of its common stock and warrants to purchase up to an aggregate of 1,272,500 shares of its common stock at a combined public offering price of $2.005 per share and accompanying warrant, including 331,956 shares of common stock and warrants to purchase 165,978 shares of common stock issued pursuant to t |
GANX Price Returns
| 1-mo | -27.23% |
| 3-mo | -4.50% |
| 6-mo | 5.30% |
| 1-year | -41.44% |
| 3-year | -74.88% |
| 5-year | N/A |
| YTD | -2.60% |
| 2023 | 4.31% |
| 2022 | -42.36% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...